Duvivier Valérie F, Delafoy-Plasse Laure, Delion Véronique, Lechevalier Patricia, Le Bail Jean-Christophe, Guillot Etienne, Pruniaux Marie-Pierre, Galzin Anne-Marie
Sanofi-Aventis R&D, Discovery Research Metabolism Department, Rueil-Malmaison, France.
Eur J Pharmacol. 2009 Aug 15;616(1-3):314-20. doi: 10.1016/j.ejphar.2009.05.024. Epub 2009 May 29.
Recent studies suggested the involvement of the endocannabinoid pathway on insulin secretion in RINm5F cells or rat islets. Animal and clinical studies have reported beneficial effects of the selective cannabinoid 1 receptor antagonist rimonabant on glucose homeostasis. The aim of this study was to investigate the in vivo effects of rimonabant on pancreatic function in Zucker Fatty rats. Zucker Fatty rats were treated with rimonabant (10 mg kg(-1) day(-1)) or vehicle for up to 3 months. Pancreatic function was assessed by oral glucose tolerance test and by static incubation of islets in the presence of different glucose concentrations. Islet morphology was assessed by immuno-histochemistry on pancreatic sections. After 3 months, there was no difference in fasting glycaemia or AUC(glucose) during oral glucose tolerance test between rimonabant- and vehicle-treated animals. However, vehicle-treated rats developed a marked hyperinsulinaemia with time in contrast to rimonabant-treated animals, which maintained at 3 months significantly lower fasting insulin levels (7.76+/-0.67 microg l(-1) vs. 5.59+/-0.59 microg l(-1), P<0.01) and lower AUC(insulin) (1380+/-98 microg l(-1)min vs. 926+/-58 microg l(-1)min, respectively, P<0.001). In static incubation, rimonabant significantly decreased insulin secretion in response to low glucose concentration (3 months: 7.68+/-1.29 vs. 12.25+/-2.01 microg l(-1) 5 islets(-1) 45 min(-1) in rimonabant and vehicle respectively, P<0.01), resulting in a trend to increase stimulation index in the presence of 16.7 mM glucose (10.64+/-0.92 vs. 8.52+/-1.70 respectively). Morphological analysis at 3 months showed that rimonabant reduced islet-cell surface (-60%) and the percentage of disorganized islets (-54%).In conclusion, our data suggest that rimonabant has a protective role against the development of hyperinsulinaemia, beta-cell dysfunction and islet modification in Zucker Fatty rats.
近期研究表明,内源性大麻素途径参与了RINm5F细胞或大鼠胰岛中的胰岛素分泌过程。动物和临床研究报告了选择性大麻素1受体拮抗剂利莫那班对葡萄糖稳态具有有益作用。本研究的目的是调查利莫那班对Zucker肥胖大鼠胰腺功能的体内影响。将Zucker肥胖大鼠用利莫那班(10毫克/千克/天)或赋形剂治疗长达3个月。通过口服葡萄糖耐量试验以及在不同葡萄糖浓度下对胰岛进行静态孵育来评估胰腺功能。通过对胰腺切片进行免疫组织化学来评估胰岛形态。3个月后,利莫那班治疗组和赋形剂治疗组动物在口服葡萄糖耐量试验期间的空腹血糖或葡萄糖曲线下面积(AUC(葡萄糖))没有差异。然而,与利莫那班治疗组动物相比,赋形剂治疗组大鼠随时间出现了明显的高胰岛素血症,利莫那班治疗组动物在3个月时的空腹胰岛素水平显著更低(分别为7.76±0.67微克/升和5.59±0.59微克/升,P<0.01),胰岛素曲线下面积(AUC(胰岛素))也更低(分别为1380±98微克/升·分钟和926±58微克/升·分钟,P<0.001)。在静态孵育中,利莫那班显著降低了对低葡萄糖浓度的胰岛素分泌(3个月时:利莫那班组和赋形剂组分别为7.68±1.29微克/升·5个胰岛-1·45分钟-1和12.25±2.01微克/升·5个胰岛-1·45分钟-1,P<0.01),导致在16.7毫摩尔/升葡萄糖存在时刺激指数有增加的趋势(分别为10.64±0.92和8.52±1.70)。3个月时的形态学分析表明,利莫那班减少了胰岛细胞表面(-60%)和结构紊乱的胰岛百分比(-54%)。总之,我们的数据表明,利莫那班对Zucker肥胖大鼠高胰岛素血症、β细胞功能障碍和胰岛改变的发展具有保护作用。